We have been featured in Yakuji Nippo for its expansion in Japan and investment in the Kawagoe site to boost solid dosage production. The article highlights the company’s focus on quality, transparency, and its commitment to strengthening Japan’s pharmaceutical supply chain. Read the article’s summary here below.
Adragos Pharma is actively seeking to expand its presence in Japan, focusing significantly on enhancing its production capabilities at the Kawagoe site in Saitama Prefecture. Acquired from Sanofi in 2023, this facility is set to increase its solid dosage production capacity to one billion tablets, with plans to further scale to a two-billion-tablet system. This expansion is part of Adragos Pharma’s commitment to bolstering the pharmaceutical supply chain in Japan, aligning with the nation’s health ministry’s objectives for a stable supply of essential medicines. The company is collaborating with pharmaceutical manufacturers and distributors to achieve these ambitious goals.
Adragos Pharma’s operational strategy centers on high-quality standards and strong compliance, supported by a customer-centric approach that values transparent communication. Streamlined processes, especially in technology transfer, help build client trust through clear and timely updates. Henny adds, “Its employees’ dedication to success and ability to adapt to the new business model were key factors. It has been recognized by global headquarters as one of the company’s most successful transformations,” underscoring how people and process improvements drive Adragos Pharma’s continued success.
The commitment to quality remains a top priority for Adragos Pharma, as it strives to uphold global standards across its operations in the U.S., Europe, and Japan. Henny emphasizes, “Quality is absolutely non-negotiable and remains our highest priority.” Guided by a corporate culture that values excellence in quality practices, the company is well-prepared to deliver high-caliber pharmaceutical products. Additionally, Adragos Pharma is exploring broader opportunities in the biopharmaceutical sector, including biosimilars, and is considering investments in new technologies such as vial and pre-filled syringe filling equipment to expand its service offerings.
As a relatively new entrant in the Japanese market, Adragos Pharma is keen to establish strong ties with potential clients. By inviting stakeholders to visit the Kawagoe site, the company aims to provide insights into its operational framework and quality-driven culture. Through a transparent and dependable business model, Adragos Pharma seeks to make a positive impression, encouraging clients to consider it as a trusted manufacturing partner. This strategy is designed to secure a stronger foothold in the Japanese pharmaceutical sector and support the company’s continued global growth.
Read the full article from Yakuji Nippo: https://yakunet.yakuji.co.jp/index.php?PAGE=LOGIN&TARGET_ID=138544
